Evidence map›Paper›PMID 32980676›Full record

ArticleVirology2020

Selection and immune recognition of HIV-1 MPER mimotopes.

Lindsay Wieczorek, Kristina Peachman, Nicholas Steers, Jesse Schoen, Mangala Rao, Victoria Polonis, Venigalla Rao

Abstract read

In one paragraph

Article in Virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.5field-weighted citation impact, top 35% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies.PLoS pathogens · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lindsay WieczorekU.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD, 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, 6720A Rockledge Drive, Bethesda, MD, 20817, USA; Catholic University of America, 620 Michigan Ave NE, Washington, DC, 20064, USA.

Kristina PeachmanU.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD, 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, 6720A Rockledge Drive, Bethesda, MD, 20817, USA.

Nicholas SteersU.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD, 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, 6720A Rockledge Drive, Bethesda, MD, 20817, USA.

Jesse SchoenU.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD, 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, 6720A Rockledge Drive, Bethesda, MD, 20817, USA.

Mangala RaoU.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD, 20910, USA.

Victoria PolonisU.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD, 20910, USA.

Venigalla RaoCatholic University of America, 620 Michigan Ave NE, Washington, DC, 20064, USA. Electronic address: rao@cua.edu.

Henry M. Jackson Foundation · USWalter Reed Army Institute of Research · USUniversity of America · US

Funding

Potent Phage T4 Derived V2 Immunogens as HIV VaccinesR01AI102725 · NIAID · CATHOLIC UNIVERSITY OF AMERICA · PI RAO, VENIGALLA B. · 2012 to 2015

$1.7M

NIAID NIH HHS R01 AI102725

6 · The paper itself

Abstract

The membrane proximal external region (MPER) of HIV-1 gp41 is targeted by several neutralizing antibodies (NAbs) and is of interest for vaccine design. In this study, we identified novel MPER peptide mimotopes and evaluated their reactivity with HIV + plasma antibodies to characterize the diversity of the immune responses to MPER during natural infection. We utilized phage display technology to generate novel mimotopes that fit antigen-binding sites of MPER NAbs 4E10, 2F5 and Z13. Plasma antibodies from 10 HIV + patients were mapped by phage immunoprecipitation, to identify unique patient MPER binding profiles that were distinct from, and overlapping with, those of MPER NAbs. 4E10 mimotope binding profiles correlated with plasma neutralization of HIV-2/HIV-1 MPER chimeric virus, and with overall plasma neutralization breadth and potency. When administered as vaccines, 4E10 mimotopes elicited low titer NAb responses in mice. HIV mimotopes may be useful for detailed analysis of plasma antibody specificity.

Indexed as

AIDS VaccinesAmino Acid SequenceAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibody SpecificityAntigens, ViralBinding, CompetitiveEnzyme-Linked Immunosorbent AssayEpitope MappingEpitopesFemaleHIV-1HIV-2HIV AntibodiesHIV Envelope Protein gp41AIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingAntigens, ViralEpitopesHIV AntibodiesHIV Envelope Protein gp41Peptide LibraryPeptidesBiopanningEpitope mappingHIV-1Membrane proximal external regionMimotopesNeutralizing antibodiesPhage display

Identifiers

PMID32980676

DOI10.1016/j.virol.2020.06.016

PMCPMC12869404

OpenAlexW3088426316

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.